Posted: April 24, 2014 at 12:42 pm
Stem Cell Therapy | bone marrow concentrate for osteoarthritis
http://www.arthritistreatmentcenter.com In the next video I #39;ll report on another study showing the effectiveness of stem cells in the treatment of osteoarthritis... New Study Shows Positive...
By: Nathan Wei
Read more:
Stem Cell Therapy | bone marrow concentrate for osteoarthritis - Video
Posted: April 24, 2014 at 12:42 pm
Anthony Nolan Final Day
This will probably be the most important post I have put on Youtube - EVER!! I have below the final day video of my Stem Cell donation to an unknown blood cancer patient. This day opened my...
By: 3ness
Continued here:
Anthony Nolan Final Day - Video
Posted: April 24, 2014 at 12:42 pm
Unclear Regulations Holding Back Stem Cell Treatments iHealthTube15
How and why is the FDA restricting stem cell therapies? What is a stem cell? Learn more from my book, "Telomere Timebombs: Defusing the terror of aging" at h...
By: Ed Park
Read more from the original source:
Unclear Regulations Holding Back Stem Cell Treatments iHealthTube15 - Video
Posted: April 24, 2014 at 12:41 pm
Stem Cell Research Documentary
This was a project I did for a C-SPAN competition my sophomore year of high school. It won an honorable mention.
By: Claire Lawson
Read more from the original source:
Stem Cell Research Documentary - Video
Posted: April 24, 2014 at 2:55 am
Royal L #39;Opulent Rejuv
Rejuvenate your skin through the activation of skin stem cells. Brightens your skin for a more even toned complexion, restores skins natural moisture to serve as barrier for enhanced hydration...
By: SariSariNZ
See more here:
Royal L'Opulent Rejuv - Video
Posted: April 24, 2014 at 2:55 am
Released: 4/21/2014 8:55 AM EDT Embargo expired: 4/23/2014 5:00 PM EDT Source Newsroom: Ohio State University Contact Information
Available for logged-in reporters only
Newswise COLUMBUS, Ohio New research suggests that attempts to isolate an elusive adult stem cell from blood to understand and potentially improve cardiovascular health a task considered possible but very difficult might not be necessary.
Instead, scientists have found that multiple types of cells with primitive characteristics circulating in the blood appear to provide the same benefits expected from a stem cell, including the endothelial progenitor cell that is the subject of hot pursuit.
There are people who still dream that the prototypical progenitors for several components of the cardiovascular tree will be found and isolated. I decided to focus the analysis on the whole nonpurified cell population the blood as it is, said Nicanor Moldovan, senior author of the study and a research associate professor of cardiovascular medicine at The Ohio State University.
Our method determines the contributions of all blood cells that serve the same function that an endothelial progenitor cell is supposed to. We can detect the presence of those cells and their signatures in a clinical sample without the need to isolate them.
The study is published in the journal PLOS ONE.
Stem cells, including the still poorly understood endothelial progenitor cells, are sought-after because they have the potential to transform into many kinds of cells, suggesting that they could be used to replace damaged or missing cells as a treatment for multiple diseases.
By looking at gene activity patterns in blood, Moldovan and colleagues concluded that many cell types circulating throughout the body may protect and repair blood vessels a key to keeping the heart healthy.
The scientists also found that several types of blood cells retain so-called primitive properties. In this context, primitive is positive because these cells are the first line of defense against an injury and provide a continuous supply of repair tissue either directly or by telling local cells what to do.
See original here:
Stem Cells in Circulating Blood Affect Cardiovascular Health
Posted: April 24, 2014 at 2:55 am
PUBLIC RELEASE DATE:
23-Apr-2014
Contact: Nicanor Moldovan Moldovan.6@osu.edu 614-247-7801 Ohio State University
COLUMBUS, Ohio New research suggests that attempts to isolate an elusive adult stem cell from blood to understand and potentially improve cardiovascular health a task considered possible but very difficult might not be necessary.
Instead, scientists have found that multiple types of cells with primitive characteristics circulating in the blood appear to provide the same benefits expected from a stem cell, including the endothelial progenitor cell that is the subject of hot pursuit.
"There are people who still dream that the prototypical progenitors for several components of the cardiovascular tree will be found and isolated. I decided to focus the analysis on the whole nonpurified cell population the blood as it is," said Nicanor Moldovan, senior author of the study and a research associate professor of cardiovascular medicine at The Ohio State University.
"Our method determines the contributions of all blood cells that serve the same function that an endothelial progenitor cell is supposed to. We can detect the presence of those cells and their signatures in a clinical sample without the need to isolate them."
The study is published in the journal PLOS ONE.
Stem cells, including the still poorly understood endothelial progenitor cells, are sought-after because they have the potential to transform into many kinds of cells, suggesting that they could be used to replace damaged or missing cells as a treatment for multiple diseases.
By looking at gene activity patterns in blood, Moldovan and colleagues concluded that many cell types circulating throughout the body may protect and repair blood vessels a key to keeping the heart healthy.
More:
Stem cells in circulating blood affect cardiovascular health, study finds
Posted: April 24, 2014 at 2:55 am
Thousand Oaks, CA (PRWEB) April 23, 2014
The Irvine Stem Cell Treatment Center, PC, located in Irvine, California, announces a free public seminar on the use of stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief.
The seminar will be held on Tuesday, April 29th at 4:00 p.m. and 7:00 p.m. at the Thousand Oaks Library, 1401 E. Janss Road, Thousand Oaks, CA.
At the Irvine Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF)). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.
ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Irvine Stem Cell Treatment Center only uses autologous stem cells from a person's own fat no embryonic stem cells are used. Our current areas of study include: Heart Failure, Emphysema, COPD, Asthma, Parkinsons Disease, Stroke, Multiple Sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Irvine Stem Cell Treatment Center, they may contact Dr. Gionis directly at (949) 679-3889, or see a complete list of the Centers study areas at: http://www.StemCellsUSA.net.
About Irvine Stem Cell Treatment Center: The Irvine Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Irvine Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Research Protections; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Info(at)StemCellsUSA(dot)net or visit our website: http://www.StemCellsUSA.net.
Continue reading here:
Irvine Stem Cell Treatment Center: Upcoming Lecture at Thousand Oaks Library
Posted: April 24, 2014 at 2:52 am
Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from Rice University's Baker Institute for Public Policy.
Published in the current issue of the journal Regenerative Medicine, the paper is based on the June 2013 U.S. Supreme Court ruling in the case Association for Molecular Pathology (AMP) v. Myriad Genetics that naturally occurring genes are unpatentable. The court case and rulings garnered discussion in the public about patenting biological materials.
"The AMP v. Myriad Genetics case raises questions about the patent system," said Kirstin Matthews, the Baker Institute fellow in science and technology policy and an expert on ethical and policy issues related to biomedical research and development. She co-authored the paper with Maude Rowland Cuchiara, the Baker Institute scholar for science and technology policy. The paper has timely significance in light of President Barack Obama's recent announcements on reforming the nation's patent process, including an initiative announced in February to "crowdsource" the review of patents.
"There are not many opportunities to challenge patents once they have been granted, and the options that are available are costly and mostly limited to lawsuits," Matthews said. Judges typically do not have the scientific knowledge to understand some of the technical arguments that are made in their courts, she said. "It may be better, as President Obama has proposed, to revise patenting guidelines at the U.S. Patent and Trademark Office based on feedback from scientists, engineers, ethicists and policy scholars as opposed to leaving it up to the courts."
Until the Supreme Court's decision, Myriad Genetics was the only company in the U.S. that could legally conduct diagnostic testing for BRCA 1 and 2, genes that are linked to familial breast and ovarian cancer. The company was granted the patents in 1998 and 2000, respectively. Myriad chose not to license the patents and harshly pursued anyone who infringed on them.
"The patenting of the BRCA genes launched a raucous debate about the ability to patent life: How do we distinguish between what is simply discovered and what is truly 'made by man'?" the authors asked.
Biotechnological inventions have been patented for several decades, though the criteria for patent eligibility have been refined through numerous court decisions, according to the authors. One of the most influential was Diamond v. Chakrabarty, which determined that "anything under the sun made by man" could be patented, leading to the diverse biotechnology patent landscape seen today, the authors said. However, biotechnological patents must meet the same requirements as all other patents, and they cannot be laws of nature, physical phenomena or abstract ideas.
The authors said the ruling could affect the patentability of other biotechnologies, like stem cells, depending on how the ruling is interpreted. Stem cells, like genes, are also isolated from the body although they do require some manipulation after isolation. But it is likely that if stem cell patents include detailed procedures for the manipulations beyond isolation, they will be upheld. "However these types of patents could also be challenged for failing to meet other patenting requirements like non-obviousness -- meaning that they were not really unique or original after all," the authors said.
Overall, it remains to be seen what impact the ruling in the AMP v. Myriad Genetics case will have on the biotech industry or if any patenting requirements will be changed in response to this or other court rulings, the authors said. So far, the patentability of biotechnological inventions appears to remain unaffected. "However, as more and more biotechnological inventions are patented, the line between what is and is not a 'product of nature' becomes blurred and will most likely continue to be decided in a courtroom," the authors said.
The authors suggest initial steps to address the current situation, including an outside review of patents before they are granted, reforming the rules of patent licensing to minimize restrictive practices and requiring detailed patent descriptions to prevent expensive and disruptive lawsuits.
View post:
New patenting guidelines needed for biotechnology, experts argue
Posted: April 24, 2014 at 2:50 am
More Media Coverage for MediVet Stem Cell Therapy at Newman Veterinary Centers - Central Florida
We are proud to offer this amazing procedure at Newman Veterinary Centers. Stem cell therapy can help pets with arthritis, hip dysplasia and many other degen...
By: Newman Veterinary Centers
See the article here:
More Media Coverage for MediVet Stem Cell Therapy at Newman Veterinary Centers - Central Florida - Video
